294 related articles for article (PubMed ID: 21221531)
1. A preliminary investigation of varenicline for heavy drinking smokers.
Fucito LM; Toll BA; Wu R; Romano DM; Tek E; O'Malley SS
Psychopharmacology (Berl); 2011 Jun; 215(4):655-63. PubMed ID: 21221531
[TBL] [Abstract][Full Text] [Related]
2. Varenicline decreases alcohol consumption in heavy-drinking smokers.
Mitchell JM; Teague CH; Kayser AS; Bartlett SE; Fields HL
Psychopharmacology (Berl); 2012 Oct; 223(3):299-306. PubMed ID: 22547331
[TBL] [Abstract][Full Text] [Related]
3. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
Psychopharmacology (Berl); 2014 Oct; 231(19):3843-53. PubMed ID: 24733235
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.
Rose JE; Behm FM
Am J Psychiatry; 2014 Nov; 171(11):1199-205. PubMed ID: 24934962
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
[TBL] [Abstract][Full Text] [Related]
6. Varenicline: a first-line treatment option for smoking cessation.
Garrison GD; Dugan SE
Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
[TBL] [Abstract][Full Text] [Related]
7. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
8. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
Ebbert JO; Hughes JR; West RJ; Rennard SI; Russ C; McRae TD; Treadow J; Yu CR; Dutro MP; Park PW
JAMA; 2015 Feb; 313(7):687-94. PubMed ID: 25688780
[TBL] [Abstract][Full Text] [Related]
9. An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.
McClure EA; Baker NL; Gipson CD; Carpenter MJ; Roper AP; Froeliger BE; Kalivas PW; Gray KM
Am J Drug Alcohol Abuse; 2015 Jan; 41(1):52-6. PubMed ID: 25062287
[TBL] [Abstract][Full Text] [Related]
10. Varenicline reduces alcohol self-administration in heavy-drinking smokers.
McKee SA; Harrison EL; O'Malley SS; Krishnan-Sarin S; Shi J; Tetrault JM; Picciotto MR; Petrakis IL; Estevez N; Balchunas E
Biol Psychiatry; 2009 Jul; 66(2):185-90. PubMed ID: 19249750
[TBL] [Abstract][Full Text] [Related]
11. The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial.
Hawk LW; Ashare RL; Lohnes SF; Schlienz NJ; Rhodes JD; Tiffany ST; Gass JC; Cummings KM; Mahoney MC
Clin Pharmacol Ther; 2012 Feb; 91(2):172-80. PubMed ID: 22130118
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
[TBL] [Abstract][Full Text] [Related]
13. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial.
Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; Brauer R; Kessler PD; Kalnik MW; Fahim RE; van Schayck OC
BMC Public Health; 2012 Dec; 12():1052. PubMed ID: 23216646
[TBL] [Abstract][Full Text] [Related]
16. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers.
Rhodes JD; Hawk LW; Ashare RL; Schlienz NJ; Mahoney MC
Psychopharmacology (Berl); 2012 Sep; 223(2):131-8. PubMed ID: 22526531
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.
Cui Q; Robinson L; Elston D; Smaill F; Cohen J; Quan C; McFarland N; Thabane L; McIvor A; Zeidler J; Smieja M
AIDS Patient Care STDS; 2012 Jan; 26(1):12-9. PubMed ID: 22007690
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates.
Rennard S; Hughes J; Cinciripini PM; Kralikova E; Raupach T; Arteaga C; St Aubin LB; Russ C;
Nicotine Tob Res; 2012 Mar; 14(3):343-50. PubMed ID: 22080588
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial.
Hughes JR; Rennard SI; Fingar JR; Talbot SK; Callas PW; Fagerstrom KO
Nicotine Tob Res; 2011 Oct; 13(10):955-64. PubMed ID: 21652735
[TBL] [Abstract][Full Text] [Related]
20. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
